Aims: Oral tongue squamous cell carcinoma (OTSCC) has a relatively poor outcome, and there is a need to identify better prognostic factors. Recently, tumour-stroma ratio (TSR) has been associated with prognosis in several cancers. The aim of this multiinstitutional study was to evaluate the prognostic value of TSR from original haematoxylin and eosin (HE)-stained tumour-resection slides in a series of early-stage (cT1-2N0) OTSCC patients. Methods and results: A TSR cutoff value of 50% was used to divide the patients into stroma-rich (≥50%) and stroma-poor (<50%) groups. The relationships between TSR and clinicopathological characteristics of 311 early-stage OTSCC cases were analysed. The prognostic value of TSR in OTSCC was calculated separately and in combination with a previously published cancer cell budding and depth of invasion (BD) prognostic model. A total of 89 cases (28.6%) belonged to the stroma-rich group. In a multivariate analysis, the stroma-rich group had worse diseasefree survival, with a hazard ratio (HR) of 1.81 [95% confidence interval (CI) 1.17-2.79, P = 0.008], and 2018 , 72, 1128 -1135 . DOI: 10.1111 higher cancer-related mortality (HR 1.71, 95% CI 1.02-2.86, P = 0.03). The combination of the highest-risk parameter scores of TSR and the BD model showed significant correlations with recurrence rate (HR 3.42, 95% CI 1.71-6.82, P = 0.004) and cancer-related mortality (HR 11.63,.31, P < 0.001).
Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers
Aims: Oral tongue squamous cell carcinoma (OTSCC) has a relatively poor outcome, and there is a need to identify better prognostic factors. Recently, tumour-stroma ratio (TSR) has been associated with prognosis in several cancers. The aim of this multiinstitutional study was to evaluate the prognostic value of TSR from original haematoxylin and eosin (HE)-stained tumour-resection slides in a series of early-stage (cT1-2N0) OTSCC patients. Methods and results: A TSR cutoff value of 50% was used to divide the patients into stroma-rich (≥50%) and stroma-poor (<50%) groups. The relationships between TSR and clinicopathological characteristics of 311 early-stage OTSCC cases were analysed. The prognostic value of TSR in OTSCC was calculated separately and in combination with a previously published cancer cell budding and depth of invasion (BD) prognostic model. A total of 89 cases (28.6%) belonged to the stroma-rich group. In a multivariate analysis, the stroma-rich group had worse diseasefree survival, with a hazard ratio (HR) of 1.81 [95% confidence interval (CI) 1.17-2.79, P = 0.008], and higher cancer-related mortality (HR 1.71, 95% CI 1.02-2.86, P = 0.03). The combination of the highest-risk parameter scores of TSR and the BD model showed significant correlations with recurrence rate (HR 3.42, 95% CI 1.71-6.82, P = 0.004) and cancer-related mortality (HR 11.63, 95% CI 3.83-35.31, P < 0.001).
Introduction
Oral tongue squamous cell carcinoma (OTSCC), which is the most common and aggressive cancer of the oral cavity, is characterised by an unpredictable prognosis even at the early stage of the disease. The incidence of OTSCC has increased worldwide even in countries where tobacco use, which is the major risk factor for oral cancer, has decreased. 1 Overall, OTSCC is associated with a high risk of occult lymph node metastasis, recurrence, and cancer-related mortality. 2, 3 Treatment planning for OTSCC is generally based on disease staging, i.e. clinical assessment of the tumour, lymph nodes, and distant metastases (cTNM staging). However, this staging system often fails to provide an accurate prediction for early-stage OTSCC. 3, 4 Therefore, there is a need for reliable and simple prognostic markers that could better identify early-stage OTSCC with aggressive behaviour. Regarding conventional haematoxylin and eosin (HE) staining, previous histopathological prognostic markers have mainly been related to cancer cells (e.g. degree of differentiation, pattern of invasion, depth of invasion, nuclear pleomorphism, and mitotic activity). However, tumour growth has been shown to also depend on tumour-surrounding stroma, i.e. the tumour microenvironment, which has an important role in cancer progression. 5 For individualised cancer management, it is therefore important to characterise both tumour cells and stroma.
Tumour-stroma ratio (TSR) has been identified recently as a useful prognostic tool in several solid tumours, including nasopharyngeal, 6 oesophageal 7 and colon 8 cancers. Evaluation of TSR in tissue sections is simple, quick, and reproducible. 7, 9 To the best of our knowledge, the prognostic significance of TSR in early-stage OTSCC has not been studied. Here, we evaluated TSR and its relationship with tumour characteristics in a multicentre cohort of early-stage OTSCC. Furthermore, we combined TSR with our previous budding and depth of invasion (BD) model 10, 11 to assess whether these three easily measured parameters from HE-stained sections could together provide a valuable estimate for early-stage OTSCC prognostication.
Materials and methods
The cohort of this study included 224 cases of earlystage OTSCC treated by surgical resection in the five Finnish University Hospitals (Helsinki, Turku, Tampere, Oulu, and Kuopio) and 87 cases treated at the A. C. Camargo Cancer Centre, São Paulo, Brazil.
10
All cases were staged according to the existing 7th edition of the AJCC cancer staging manual. 12 The original routine histopathological slides and follow-up data were collected for all cases. Ethics approval of the institutional review boards of all participating hospitals was obtained, as was approval of the Brazilian Human Research Ethics Committee and the Finnish National Supervisory Authority for Welfare and Health (VALVIRA).
To ensure proper evaluation of TSR, training sessions were arranged and guided by an experienced head and neck pathologist (I.L.). Two researchers (A.A. and I.H.) blinded to patient data scored the cases independently. In cases of disagreement, a review session was arranged. We scanned the whole tumour under low magnification (94) to select a field with the highest amount of stroma, and, at the same time, with cancer cells at all four sides of the field. 13 As noted previously, areas rich in stroma were usually located near the site of deepest invasion. 7 Under higher magnification (910), the selected field was scored as stroma-poor (<50%) or stroma-rich (≥50%) (Figure 1 ). If a tumour was heterogenic (i.e. it had both stroma-poor and stroma-rich areas), stroma-rich areas were selected and deemed to be decisive, as previously described. 7, 14 Areas of muscle invasion and necrosis were visually excluded.
The prognostic value of TSR was first separately analysed. Additionally, risk scores were constructed by combining TSR and the BD model. The BD model parameters for these same samples have been previously analysed and published. 10 TSR and BD combination scores were set as follows: score 0 (low risk)-all three markers (tumour budding, depth of invasion, and TSR) were below the cutoff points (i.e. <5 buds, depth of <4 mm, and <50% stroma); score 1 (intermediate risk)-only one of the markers exceeded the cutoff point; score 2 (high risk)-two of the markers exceeded the cutoff point; and score 3 (extremely high risk)-all markers exceeded the cutoff point.
The histological risk score was evaluated as previously described by Brandwein-Gensler. 15, 16 Cases with score 0 were considered to be at low risk; cases with score 1 or 2 were considered to be at intermediate risk; and cases with score ≥3 considered to be at high risk. 16 Survival analyses were conducted with SPSS STATISTICS (version 24.0). Univariate analysis and Kaplan-Meier curves were created for both diseasefree survival (DFS) and disease-specific survival (DSS). In multivariate analysis, classic prognostic factors, such as age, gender, clinical stage, World Health Organisation (WHO) tumour grade, and perineural invasion (PNI), were included in the multivariate Cox regression model together with TSR or with the combined scores of TSR and the BD model. The relationship between TSR and the classic prognostic variables was also analysed.
Results
The clinicopathological characteristics of this multicentre cohort have been published previously. 10 In brief, the 311 patients comprised 165 males and 146 females; 124 cases were clinically T1N0M0, and 187 cases were T2N0M0. All patients had been treated by surgical resection. Eighty-nine cases (28.6%) were classified as stroma-rich and 222 cases (71.4%) as stroma-poor. In the present study, there was concordance between the observers in classifying the tumours into stroma-poor (<50%) or stroma-rich (≥50%) in 96% of the cases (Cohen's kappa = 0.91).
The relationship between TSR and clinicopathological characteristics is summarised in Table 1 . No associations were found between TSR and age, gender, cTNM stage, or WHO grade (two-sided P > 0.05). TSR was associated with PNI (two-sided P = 0.04).
U N I V A R I A T E S U R V I V A L A N A L Y S I S
Stroma-rich cases were associated with higher rates of recurrence, with a hazard ratio (HR) of 1.67 and a 95% confidence interval (CI) of 1.09-2.56 (P = 0.02). In addition, there were more cancerrelated deaths among stroma-rich cases (HR 1.69, 95% CI 1.02-2.79, P = 042). Kaplan-Meier curves ( Figure 2 ) showed a worse prognosis (both DFS and DSS) for stroma-rich cases. The combined highest scores of TSR and the BD model (Table 2) were associated with higher rates of recurrence, with an HR of 2.82 (95% CI 1.46-5.42, P = 0.014), and there were also more cancer-related deaths among these cases (HR 10.43, 95% CI 3.51-31.01, P < 0.001).
Among the classic prognostic factors (age, gender, cTNM stage, WHO tumour grade, and PNI) that were included in the survival analysis (Table 2) , only age of the patient was associated with DFS (HR 1.79, 95% CI 1.14-2.79, P = 0.01) and DSS (HR 1.87, 95% CI 1.09-3.18, P = 0.02). The histological risk score of Brandwein-Gensler et al. 
Discussion
Several studies have evaluated prognostic markers for OTSCC, 2,17 but most of these studies have significant shortcomings: early and late stages are combined, cancers from different subsites of the tongue (oral and base) are pooled, and patient cohorts are rather small and from a single institute. Moreover, the prognostic studies have mainly focused on features related to cancer cells. TSR has already been investigated in several solid cancers as shown by a recent meta-analysis, 13 and a high proportion of stroma in cancer tissue was associated with poor clinical outcome. Here, for the first time, we have evaluated the prognostic value of TSR in a large international multicentre cohort of early-stage OTSCC, and found that TSR is useful for early-stage OTSCC prognostication. The prognostic value was improved if TSR analysis was combined with the BD model. 10 The 7th edition of the AJCC cancer staging manual 12 does not provide valuable prognostic power for earlystage (cT1-2N0M0) OTSCC, and has therefore been widely criticised. 18 For this reason, the 8th edition of the AJCC cancer staging manual, 19 which was released recently, has incorporated depth of invasion in the T-category. It is of note that the AJCC emphasised that depth of invasion (and not tumour thickness) should be used for the T-category. 19 The 8th edition of the AJCC cancer staging manual has been applied for staging of new cases since January 2018, and there is a need for further research to evaluate the prognostic value of this new staging in early OTSCC (cT1-2N0M0).
At the same time, the WHO histopathological grading system, which is based on the differentiation of cancer cells, has also been criticised because of its low prognostic performance for early OTSCC. 3, 20 Furthermore, a histological risk score has been introduced by Brandwein-Gensler et al. as a prognostic model for OSCC. 15, 16 However, our previous study of a Finnish cohort 21 and the current study of a Finnish and Brazilian cohort did not find prognostic usefulness for this histological risk score in early-stage OTSCC. Similarly, other recent studies have reported low prognostic performance for the histological risk score. 11, 20, 22 Such shortcomings in prognostic power may lead to inappropriate management, with either ineffective treatment or overtreatment. To date, all histopathological features incorporated in routine clinical pathology reports are related only to cancer cells. Although the role of the stroma in cancer progression has been recognised for more than a decade, [23] [24] [25] its applications in interpreting cancer specimens, including OTSCC, have been very limited. In this study, we found that OTSCC patients with stroma-rich tumours had a worse prognosis than patients with stroma-poor tumours. Importantly, TSR showed considerably better prognostic power than conventional cTNM staging and histopathological WHO tumour grade (Table 2) . It is of note that concordance between the observers in this study was very good (96%), and almost similar concordance (94%) on TSR has been reported for other cancers. 6, 26 Also, the kappa values indicate good agreement between observers in this and previous studies. 6, 7, 9, 14 Combination of TSR with the BD model (including tumour depth of invasion and tumour budding 10 ) showed even greater prognostic value in multivariate analysis. In the patients with the highest scores, risks of recurrence and OTSCC-related mortality were 3.4-fold and 11.6-fold higher, respectively. These highest-risk patients thus had early-stage cancer with abundant stroma (≥50%), five or more cancer cell buds, and an invasion depth of at least 4 mm. In such patients, a multimodality treatment approach, including prophylactic neck dissection and possible adjuvant radiotherapy, should be considered even though such cases are clinically diagnosed as earlystage (cT1-2N0) tumours.
Tumour-host interactions play an important role in cancer progression, during which the crosstalk between tumour cells and the surrounding stroma is a continuous process. 5, 27 Different types of immune cell are located in the tumour stroma and have key roles in tumour progression. For example, tumourassociated macrophages have been shown to promote tumour growth and inhibit antitumour immune responses, and their number is positively associated with poor prognosis in OSCC. [28] [29] [30] Inflammatory cells play an important role in cancer progression and predict the prognosis of OSCC. 31 Moreover, the density of the inflammatory infiltrate in OTSCC is significantly correlated with cancer-associated fibroblasts (CAFs). 27 Vascular endothelial growth factor and other growth factors such as epidermal growth factor are derived from stromal cells and endothelial cells, and promote tumour angiogenesis, which enhances tumour growth, survival, and metastasis. 13, [32] [33] [34] In OTSCC, CAFs identified by the use of a-smooth muscle actin have been reported as key players in tumour progression, 35 and they serve as an important prognostic marker in oral cancers, including all stages of OTSCC. 36, 37 In addition, stromal compounds, such as activin A, tenascin-C, and fibronectin, have shown prognostic power in OTSCC. 38, 39 However, the use of immunohistochemistry for such biomarkers increases costs, and the staining results may be, depending on the antibody used and the ligand expression level, difficult to analyse objectively. The benefit of TSR is that it can be evaluated from routine HE-stained slides. Evaluation of TSR in combination with cancer invasion parameters, such as tumour budding and depth of invasion, provides prognostication superior to evaluation of each parameter separately.
In conclusion, visual analysis of TSR is useful for early-stage OTSCC prognostication. Combining TSR analysis with features of cancer cells, such as budding and depth of invasion, could assist clinicians in identifying the early-stage OTSCC patients who are most likely to have a poor prognosis and might benefit from more aggressive treatment. TSR and the BD model are simple to evaluate from routine diagnostic slides and do not require additional staining. The results reported here need to be validated in independent studies before these prognostic parameters are included in routine pathology reports. BD, budding and depth of invasion; CI, confidence interval; HR, hazard ratio; HRS, histological risk score; PNI, perineural invasion. *The scores of TSR were combined with our previous BD model as explained in Materials and methods.
